Figure 1: Injection Pattern For Intradetrusor Injections For Treatment Of Overactive Bladder And Detrusor Overactivity Associated With A Neurologic Condition (Botox 01)
Botox Injection, Powder, Lyophilized, For Solution
Product Images NDC 85766-155
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Botox (NDC 85766-155). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Sportpharm Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Diagrams 1-4: Recommended Injection Sites (a Through G) For Chronic Migraine (Botox 02)
A Close Up Of A Piece Of Paperdescription Automatically Generated (Botox 03)
Figure 3: Injection Sites For Adult Lower Limb Spasticity (Botox 04)
Figure 4: Injection Sites For Pediatric Upper Limb Spasticity (Botox 05)
This is a description of two forearm muscles: the flexor carpi radialis and the flexor digitorum sublinis (also known as flexor digitorum superficialis). These muscles are important for wrist and finger movements.*
Figure 5 (Botox 06)
Figure 6: Injection Pattern For Primary Axillary Hyperhidrosis (Botox 07)
Figure 7: Mean Change From Baseline In Daily Frequency Of Urinary Incontinence Episodes Following Intradetrusor Injection In Study Oab-1 (Botox 08)
Figure 8: Mean Change From Baseline In Daily Frequency Of Urinary Incontinence Episodes Following Intradetrusor Injection In Study Oab-2 (Botox 09)
Figure 9: Mean Change From Baseline In Weekly Frequency Of Urinary Incontinence Episodes During Treatment Cycle 1 In Study Ndo-1 (Botox 0a)
Figure 10: Mean Change From Baseline In Weekly Frequency Of Urinary Incontinence Episodes During Treatment Cycle 1 In Study Ndo-2 (Botox 0b)
Figure 11: Mean Change From Baseline In Number Of Headache Days For Study 1 (Botox 0c)
Figure 12: Mean Change From Baseline In Number Of Headache Days For Study 2 (Botox 0d)
Figure 13: Modified Ashworth Scale Ankle Score For Study 6 – Mean Change From Baseline By Visit (Botox 0e)
Figure 14: Clinical Global Impression By Physician For Study 6 – Mean Scores By Visit (Botox 0f)
Figure 15: Modified Ashworth Scale Score For Study 1 (pediatric Upper Limb Spasticity, Modified Intent-to-treat Population) – Mean Change From Baseline By Visit (Botox 10)
Figure 16: Clinical Global Impression Of Overall Change For Study 1 (pediatric Upper Limb Spasticity, Modified Intent-to-treat Population) – Mean Scores By Visit (Botox 11)
Figure 17: Modified Ashworth Scale Ankle Score For Study 2 (pediatric Lower Limb Spasticity, Modified Intent-to-treat Population) – Mean Change From Baseline By Visit (Botox 12)
Figure 18: Clinical Global Impression Of Overall Change For Study 2 (pediatric Lower Limb Spasticity, Modified Intent-to-treat Population) – Mean Scores By Visit (Botox 13)
1 (Label)
This document lists different variations of BOTOX for Injection products by SPORTPHARM, including quantities and National Drug Codes (NDC). The products contain OnabotulinumtoxinA and are available in different quantities such as 100 and 200 units. Manufacturing information by ABbVis e is provided as well.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
